Form 4: Revolution Medicines Exec Sells Shares

Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc., reported a transaction involving the sale of common stock to cover tax withholding obligations.

Summary

• Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc., reported a transaction on June 16, 2026.
• The transaction involved the sale of 10,020 shares of common stock.
• This sale was executed as part of a Rule 10b5-1 trading plan adopted on May 31, 2023, to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs).
• The weighted average sale price was $156.1188 per share, with individual trades ranging from $156.1105 to $156.8250.
• Following this transaction, Goldsmith beneficially owns 267,330 shares directly.
• Additional holdings include 594,060 shares held indirectly through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, 64,424 shares through the Jonathan Goldsmith Revocable Trust, and 64,424 shares through the Rebecca Goldsmith Revocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an executive selling shares can be a negative signal, the stated reason for tax withholding under a pre-established 10b5-1 plan mitigates significant concern.

Negatives

• The sale of shares by a key executive could be perceived negatively by the market, although it is stated to be for tax withholding purposes.

Risks

• The transaction was executed under a Rule 10b5-1 plan, which is designed to provide an affirmative defense against allegations of insider trading. However, the existence of such plans can sometimes lead to scrutiny.
• While the sale is for tax withholding, any significant stock sales by executives can raise concerns about their confidence in the company's future performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports a past transaction.

Management Comments

• The transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ('RSUs') after July 15, 2023.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that insider stock sales, even those for tax withholding purposes under a Rule 10b5-1 plan, are common for executives as RSUs vest. The key is the volume and frequency of such sales relative to total holdings and the company's performance.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor negative signal, but the explanation for tax withholding under a 10b5-1 plan should temper concerns.
• Employees: The transaction relates to executive compensation and tax obligations, with no direct impact on other employees.
• Management: The sale fulfills tax obligations for the executive, allowing them to retain net shares after withholding.

Next Steps

• The reporting person will continue to hold shares indirectly through various trusts.
• The company may provide further information on the transaction if requested by the SEC, issuer, or a security holder.

Key Dates

Keywords

Revolution Medicines, RVMD, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Executive Compensation, Tax Withholding, Restricted Stock Units, Beneficial Ownership